Agios second shot at sickle cell disease falls short on July 22, 2026 Agios Pharmaceuticals Anemia, Sickle Cell Decision development aspects discontinued mitapivat PK activator PYRUKYND tebapivat United States Food and Drug Administration +
Agios scraps sickle cell program over lackluster Phase 2 data on July 21, 2026 AGIO Agios Pharmaceuticals Anemia, Sickle Cell discontinued hemoglobin response lackluster data Programs - Publication Format Sarah Gheuens tebapivat yruvate Kinase Activator [EPC] +